VI

Vilya

<UNKNOWN>, US · 5 known investors

vilyatx.com ↗

Vilya designs novel macrocycles using AI and computational biology to create medicines that don't exist in nature. The company develops therapeutics for disease by generating entirely new molecules with the targeting precision of antibodies but in pill form.

Founders & leadership

DB

David BakerScientific Founder

PS

Patrick Salveson, PhDCo-Founder, CTO

AM

Adam Moyer, PhDCo-Founder, VP of Molecular Design

DB

David Baker, PhDNobel laureate, Co-Founder, Director, IPD UW, Prof. Biochemistry

GB

Gaurav Bhardwaj, PhDCo-Founder, UW, Asst. Prof. Medicinal Chemistry

LS

Lance Stewart, PhD, MBACo-Founder, CSO & COO, IPD

NH

Nao Hiranuma, PhDCo-Founder, Director of Machine Learning

CH

Cyrus Harmon, PhDCEO and President

Investors · 5

AR

ARCH Venture PartnersChicago · $50K – $250M

MA

Madrona Venture GroupSeattle · $2M – $10M

ME

Menlo VenturesSan Francisco · $1M – $20M

NV

NVenturesreportedSingapore · $25K – $2.5M

NV

NVenturesreportedSanta Clara